MolMed: New Phase II Data on Investigational Drug NGR-hTNF Presented at ASCO MarketWatch (press release) ... II clinical trials of its investigational drug NGR-hTNF in as many different types of solid tumours, together with an update on the clinical development of the TK therapy in association with bone marrow transplantation for acute leukemia patients. |
